戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              PEPCK activity was elevated threefold in lung cancer sam
2                                              PEPCK and G6Pase transcript levels are downregulated in
3                                              PEPCK and glucose-6-phosphatase mRNA levels were increas
4                                              PEPCK depletion also attenuated Mtb in IFNgamma-deficien
5                                              PEPCK enzymatic activity is half that of primary hepatoc
6                                              PEPCK-C(mus) mice had an enhanced exercise capacity, wit
7                                              PEPCK-C(mus) mice had an extended life span relative to
8                                              PEPCK-M was acutely silenced in gluconeogenic tissues of
9 sion of phosphoenolpyruvate carboxykinase 2 (PEPCK), glucose-6-phosphatase (G6Pase) and suppressed he
10 1.0+/-0.8), pyruvate cycling (154.4+/-43.4), PEPCK flux (221.7+/-47.6), and TCA cycle flux (49.1+/-16
11 ffect of 3-mercaptopicolinic acid (3-MPA), a PEPCK inhibitor, on C2C12 muscle cells.
12     Only caMKK6 activated transcription of a PEPCK-luciferase reporter construct.
13 ctural and kinetic characterization of A467G-PEPCK supports our model of the role of the active site
14 lthough cytosolic PEPCK (PEPCK-C) is absent, PEPCK-M message and protein were detected in INS-1 832/1
15              In addition, MKP-3 can activate PEPCK promoter in synergy with dexamethasone in hepatoma
16 f glycerol in promastigotes and amastigotes; PEPCK participates in the entry of aspartate in promasti
17 gulate other FoxO1 target genes (IGFBP-1 and PEPCK) but not serpinB1 expression in mouse primary hepa
18 te is diagnostic of pyruvate carboxylase and PEPCK flux in the liver.
19 YC), whereas ME abundance did not change and PEPCK abundance declined.
20 ated FOXO1/phospho-FOXO1 protein content and PEPCK/G6Pase messenger RNA (mRNA) expression did not rev
21 oduction (P < 0.02 vs. genotype control) and PEPCK gene expression.
22 vator-1alpha co-activation of the CYP7A1 and PEPCK genes.
23 sulted in significant increase of CYP7A1 and PEPCK mRNA expression and the rate of bile acid synthesi
24 e PPDK gene in the wild-type (Deltappdk) and PEPCK null (Deltappdk/Deltapepck) backgrounds.
25 important for the prepartum rises in G6P and PEPCK activities in the liver and kidney and may mediate
26  (8-12 microg (kg body wt)-1 day-1), G6P and PEPCK activities in the liver and kidney were greater th
27              At 140-145 days, tissue G6P and PEPCK activities in TX fetuses were lower than in intact
28 line-infused fetuses, but only renal G6P and PEPCK increased to the level seen close to term.
29 ic genes (glucose-6-phosphatase [G6Pase] and PEPCK) contributes to hyperglycemia.
30 of glucocorticoid receptor, 11beta-HSD1, and PEPCK, and these effects were abolished by RU486.
31 emia, glycemia after pyruvate injection, and PEPCK protein expression in the liver of HFD-fed and db/
32 of DBC1 knockdown on Rev-erbalpha levels and PEPCK expression, suggesting that the mechanism of PEPCK
33 increases in phosphorylation of p38 MAPK and PEPCK mRNA.
34 gluconeogenesis by decreasing Glc-6-Pase and PEPCK gene expression through NR1D1.
35 genesis and the expression of Glc-6-Pase and PEPCK.
36 f leptin on gluconeogenesis, Glc-6-Pase, and PEPCK were abolished, and a marked suppression of glycog
37 profound increase in expression of PHGDH and PEPCK-M in skeletal muscle, implicating a role for biosy
38 ydrate response element-binding protein, and PEPCK mRNAs were unaffected in SMLPL(-/-) mice, but pero
39  mouse lungs but also failed to survive, and PEPCK depletion during the chronic phase of infection re
40                TR4 transactivates the 490-bp PEPCK promoter-containing luciferase reporter gene activ
41 (G6P) and phosphoenolpyruvate carboxykinase (PEPCK) activities were investigated in sheep fetuses aft
42 inhibited phosphoenolpyruvate carboxykinase (PEPCK) and accelerated fibroblast cell migration up to 3
43 ession of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase, catalytic (G6Pc).
44 ic enzyme phosphoenolpyruvate carboxykinase (PEPCK) and impairs insulin signalling in muscle.
45 n enzymes phosphoenolpyruvate carboxykinase (PEPCK) and malic enzyme (ME) did not change.
46 c enzymes phosphoenolpyruvate carboxykinase (PEPCK) and phosphoenolpyruvate carboxykinase 2 (PCK2) to
47 cytosolic phosphoenolpyruvate carboxykinase (PEPCK) and plastidic NADP-dependent malic enzyme (ME) on
48 -Pase and phosphoenolpyruvate carboxykinase (PEPCK) by apoA-IV was determined by luciferase activity
49 lycosomal phosphoenolpyruvate carboxykinase (PEPCK) by EP and again found that the intradermal route
50           Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the first committed step of gluconeogen
51 ic enzyme phosphoenolpyruvate carboxykinase (PEPCK) demonstrate that PEPCK contains a 10-residue Omeg
52  discrete phosphoenolpyruvate carboxykinase (PEPCK) enzymes in the parasite, one of which resides in
53           Phosphoenolpyruvate carboxykinase (PEPCK) expression plays a critical role in the modulatio
54 hesis and phosphoenolpyruvate carboxykinase (PEPCK) gene in gluconeogenesis.
55       The phosphoenolpyruvate carboxykinase (PEPCK) gene is a case in point.
56 vation of phosphoenolpyruvate carboxykinase (PEPCK) gene transcription in response to all-trans-retin
57 lation of phosphoenolpyruvate carboxykinase (PEPCK) in wild-type (WT) mouse liver.
58           Phosphoenolpyruvate carboxykinase (PEPCK) is a gluconeogenic enzyme with a cytosolic (Pck1/
59           Phosphoenolpyruvate carboxykinase (PEPCK) is an essential metabolic enzyme operating in the
60           Phosphoenolpyruvate carboxykinase (PEPCK) is regulated solely by alterations in gene expres
61           Phosphoenolpyruvate carboxykinase (PEPCK) is well known for its role in gluconeogenesis.
62 -specific phosphoenolpyruvate carboxykinase (PEPCK) null mice, when fasted, maintain normal whole bod
63  used the phosphoenolpyruvate carboxykinase (PEPCK) promoter to generate transgenic mice in which Cre
64 alyzed by phosphoenolpyruvate carboxykinase (PEPCK) provides significant insight into the chemical me
65 soform of phosphoenolpyruvate carboxykinase (PEPCK) reported in the PEPCK-Mn2+, -Mn2+-oxaloacetic aci
66 ic enzyme phosphoenolpyruvate carboxykinase (PEPCK) transcription and associated transcription factor
67 iption of phosphoenolpyruvate carboxykinase (PEPCK), a key regulator of gluconeogenesis, by consuming
68 ence that phosphoenolpyruvate carboxykinase (PEPCK), an enzyme involved in malate metabolism and gluc
69 ic genes, phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase (G6Pase), and NAD(+) l
70  (PGC-1), phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase expression.
71 ase (GK), phosphoenolpyruvate carboxykinase (PEPCK), and pyruvate phosphate dikinase (PPDK) in glucon
72 etate via phosphoenolpyruvate carboxykinase (PEPCK), forward TCA cycle flux of [4-(13)C]oxaloacetate
73 levels of phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase, and peroxisome proliferat
74 c enzyme, phosphoenolpyruvate carboxykinase (PEPCK), has been shown to provide metabolites for cell g
75 -1alpha), phosphoenolpyruvate carboxykinase (PEPCK), pyruvate carboxylase, and glucose-6-phosphatase,
76 lation of phosphoenolpyruvate carboxykinase (PEPCK), the key gene in gluconeogenesis, is critical for
77        In phosphoenolpyruvate carboxykinase (PEPCK)-GFP mice, serial MPM found PEC-to-podocyte migrat
78 D-ME) and phosphoenolpyruvate carboxykinase (PEPCK).
79 Pase) and phosphoenolpyruvate carboxykinase (PEPCK).
80 ic enzyme phosphoenolpyruvate carboxykinase (PEPCK).
81 enic gene phosphoenolpyruvate carboxykinase (PEPCK).
82 Pase) and phosphoenolpyruvate carboxykinase (PEPCK).
83 lpha) and phosphoenolpyruvate carboxykinase (PEPCK).
84 ession of phosphoenolpyruvate carboxykinase (PEPCK).
85 Pase) and phosphoenolpyruvate carboxykinase (PEPCK).
86 , such as phosphoenolpyruvate carboxykinase (PEPCK).
87 cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C) and associated pathways.
88 rm of the phosphoenolpyruvate carboxykinase (PEPCK-C) gene is selectively expressed in several tissue
89 soform of phosphoenolpyruvate carboxykinase (PEPCK-M) is the GTPase linking hydrolysis of mtGTP made
90 chondrial phosphoenolpyruvate carboxykinase (PEPCK-M), encoded by the nuclear PCK2 gene, links TCA cy
91 d genes (phosphoenolpyruvate carboxykinase - PEPCK, glucocorticoid receptor - GR, and Vtg) in liver a
92 ressor of phosphoenolpyruvate carboxykinase, PEPCK) is a methanol- and biotin starvation-inducible zi
93 riptions of phosphoenolpyruvate carboxylase (PEPCK) and glucose-6-phosphatase (G6Pase) genes.
94 f other key regulatory proteins that control PEPCK-C gene transcription also likely contributed to th
95                           Although cytosolic PEPCK (PEPCK-C) is absent, PEPCK-M message and protein w
96 s lacking in plastidic NADP-ME and cytosolic PEPCK activities revealed differential changes in overal
97 c fluxes in livers lacking hepatic cytosolic PEPCK by NMR using 2H and 13C tracers.
98                    Inactivation of cytosolic PEPCK affected the respiration rate, which suggests that
99               The present study demonstrates PEPCK-M overexpression in tumorigenic cells as well as t
100 ex/RA has a synergistic effect on endogenous PEPCK gene expression in rat hepatocytes and H4IIE hepat
101 cells, pterosin A inhibited inducer-enhanced PEPCK expression, triggered the phosphorylations of AMPK
102 s SREBP1c, transmembrane protein FAS, enzyme PEPCK, and protein HSL).
103 e up-regulation of the rate-limiting enzymes PEPCK and G6Pc.
104 ey hepatic glucose production (HGP) enzymes, PEPCK and glucose-6-phosphatase, and increased glycogen
105  alpha-skeletal actin gene promoter, express PEPCK-C in skeletal muscle (1-3 units/g).
106                                     Finally, PEPCK-M knockdown using either siRNA or shRNA were suffi
107 ulin represses transcription of the gene for PEPCK-C by inducing SREBP-1c production in the liver, wh
108 tion inhibited transcription of the gene for PEPCK-C in part by deacetylation of HNF4alpha.
109  as a new posttranslational modification for PEPCK, 2) describes a pathway by which transcriptional i
110       IsoNAM decreased the level of mRNA for PEPCK-C but had no effect on mRNA for glucose-6-phosphat
111          We show here an unexpected role for PEPCK in promoting cancer cell proliferation in vitro an
112  together, these data demonstrate a role for PEPCK that links metabolic flux and anabolic pathways to
113 cells and 41% of PEP in rat islets came from PEPCK-M.
114 f PEPCK-C knock-out livers, hepatocytes from PEPCK-M-deficient livers maintained normal oxidative fun
115 nate was completely abolished in livers from PEPCK KO mice, indicating that the major pathway for ent
116 patic gluconeogenic genes, including G6Pase, PEPCK, and FOXO1.
117  expression of the glucagon receptor (GCGR), PEPCK, and genes involved in amino acid metabolism and u
118  decreased expression of gluconeogenic genes PEPCK and G-6-Pase, enhanced insulin-induced suppression
119 eduction of the expression of two key genes: PEPCK (phosphoenolpyruvate carboxykinase) and SREBP-1c (
120                 When linked to GFP or to GFP-PEPCK-C each of the novel NLS motifs was sufficient to d
121     Our results demonstrated that indeed GK, PEPCK, and PPDK are key players in the gluconeogenesis p
122 he half-life of various chimeric beta-globin-PEPCK (betaG-PCK) mRNAs in LLC-PK -F(+) cells.
123 icator of TCA flux that is crucial for GSIS, PEPCK-M is a strong candidate to link mtGTP synthesis wi
124 the identification of a new pathway, TR4 --&gt; PEPCK --> gluconeogenesis --> blood glucose, which may a
125 for phosphoenolpyruvate carboxykinase (GTP) (PEPCK-C) (EC 4.1.1.32) was linked to the alpha-skeletal
126  of phosphoenolpyruvate carboxykinase (GTP) (PEPCK-C).
127  of phosphoenolpyruvate carboxykinase (GTP) (PEPCK-C).
128 phosphoenolpyruvate (PEP) carboxykinase (GTP-PEPCK) were investigated.
129 d basal glucose production rates and hepatic PEPCK and glucose-6-phosphatase expression, which were n
130 r in intact and TX fetuses; however, hepatic PEPCK was increased by TX.
131 roscopy to show that in mice lacking hepatic PEPCK, 1) whole-body glucose turnover is only slightly d
132 an increase in the expression of the hepatic PEPCK depending on previous metabolic status.
133          Thus, although mice without hepatic PEPCK have markedly impaired hepatic gluconeogenesis, th
134                                     However, PEPCK and G6Pc expression remained unchanged.
135                                     However, PEPCK is also a key regulator of TCA cycle flux.
136                                     However, PEPCK-M is present in a variety of non-gluconeogenic tis
137                                    The human PEPCK crystal structure suggests that Asp(78) influences
138                                   Changes in PEPCK appear to have little or no acute effect on glucon
139 h of the study, despite a marked decrease in PEPCK content, suggesting poor control strength for this
140 rexpression of DBC1 results in a decrease in PEPCK mRNA and protein levels.
141 rease in SREBP-1c mRNA and a 95% decrease in PEPCK mRNA.
142 y investigate the roles of the lid domain in PEPCK function, we introduced three mutations that repla
143         DBC1 absence leads to an increase in PEPCK mRNA and protein expression.
144 suggested that the pH-responsive increase in PEPCK mRNA in LLC-PK1-FBPase+ cells is mediated by a p38
145          Thus, the pH-responsive increase in PEPCK mRNA in the kidney is mediated by the p38 MAPK sig
146 ) and 7 (p < 0.01), and a 2-fold increase in PEPCK-M protein expression at day 7 (p < 0.01).
147 l by 4 h, despite a substantial reduction in PEPCK protein, as gluconeogenically-derived carbon was r
148 se in insulin, despite eventual reduction in PEPCK protein, supporting the concept that PEPCK has poo
149 ound that conditional inactivation of VHL in PEPCK-Cre mutants resulted in renal cyst development tha
150 aling pathways are responsible for increased PEPCK-M levels.
151 ontrast, ectopic expression of TR4 increased PEPCK gene expression and hepatic glucose production in
152 in high plasma glucose content by increasing PEPCK and G6P mRNA level.
153 nthrin, and 3-PBA decreased cortisol-induced PEPCK gene expression, while o,p'-DDT and methoxychlor i
154  with exogenous LPA blunted glucagon-induced PEPCK expression and glucose production.
155 on; in cells lacking NR1D1, fails to inhibit PEPCK and Glc-6-Pase gene expression; and stimulates hig
156  were unable to confirm that 3-MPA inhibited PEPCK-M enzyme activity as 3-MPA interfered with the PEP
157 ins its profusely studied cytosolic isoform (PEPCK-C) potentiating gluconeogenesis and TCA flux.
158  although loss of the mitochondrial isoform (PEPCK-M) has never been assessed.
159 lar orphan nuclear receptor 4 (TR4) as a key PEPCK regulator modulating PEPCK gene via a transcriptio
160 d liver phosphoenolpyruvate carboxyl kinase (PEPCK) expression in diabetic mice.
161 n of phosphoenolpyruvate carboxylase kinase (PEPCK), fructose-1,6-bisphosphatase (FBPase), and glucos
162 Upon an extended 24-h fast, livers that lack PEPCK exhibit both 2-fold lower glucose production and o
163 uconeogenesis rates from hepatocytes lacking PEPCK-M are severely reduced for lactate, alanine, and g
164                     Importantly, Mtb lacking PEPCK not only failed to replicate in mouse lungs but al
165                                 In the liver PEPCK-M adjoins its profusely studied cytosolic isoform
166 expected and important role of mitochondrial PEPCK in cancer metabolism.
167  4 (TR4) as a key PEPCK regulator modulating PEPCK gene via a transcriptional mechanism.
168  activity of PEPCK-C of 9 units/g of muscle (PEPCK-C(mus) mice).
169 ta-shRNA significantly reduced or normalized PEPCK expression, with no change in PGC-1alpha or FOXO1
170  (PGC1alpha), a transcriptional activator of PEPCK.
171 s together produced mice with an activity of PEPCK-C of 9 units/g of muscle (PEPCK-C(mus) mice).
172 e mitochondrial deficiency characteristic of PEPCK-C knock-out livers, hepatocytes from PEPCK-M-defic
173 ivator 1 alpha (PGC1alpha), a coactivator of PEPCK and G6Pase transcription.
174 s transactivation activity in the context of PEPCK gene transcription.
175                          The contribution of PEPCK-M to overall PEP synthesis more than tripled with
176  islets measured substantial contribution of PEPCK-M to the synthesis of PEP.
177         Finally, we show that the effects of PEPCK on glucose metabolism and cell proliferation are i
178 ator holocomplex and regulates expression of PEPCK (phosphoenolpyruvate carboxykinase), G6P (glucose-
179 oviral infection increased the expression of PEPCK and G6Pase genes and led to elevated glucose produ
180 sts, accompanied with enhanced expression of PEPCK and G6Pase genes.
181 nd that apoA-IV suppresses the expression of PEPCK and Glc-6-Pase in hepatocytes; decreases hepatic g
182                The FFA-induced expression of PEPCK and PGC-1alpha genes and gluconeogenesis in isolat
183 vels of Foxo1 protein and mRNA expression of PEPCK by 48 +/- 4% and G6Pase by 64 +/- 3%.
184 er and insulin sensitivity and expression of PEPCK mRNA in db/db mice and db/+ controls.
185 in patients with T2DM, hepatic expression of PEPCK or G6Pc was not increased.
186              Surprisingly, the expression of PEPCK or G6Pc was not increased.
187 sphorylation of FOXO1, reduced expression of PEPCK, and increased glucokinase expression resulting in
188 urn be attributed to decreased expression of PEPCK, FBPase, and G6Pase due to increased acetylation o
189 tes glucose metabolism and the expression of PEPCK.
190    Both cytosolic and mitochondrial forms of PEPCK were found to undergo ADP-ribosylation.
191 erence (RNAi) vector blocks the induction of PEPCK and G6P, and blunts hepatic glucose output.
192 ic differentiation through the inhibition of PEPCK-M.
193 re we show that the mitochondrial isoform of PEPCK (PCK2) is expressed and active in three lung cance
194  been attributed to the cytosolic isoform of PEPCK (PEPCK-C), although loss of the mitochondrial isof
195 e structures of the mitochondrial isoform of PEPCK reported are complexed with Mn2+, Mn2+-PEP, or Mn2
196  of p38 MAPK and an increase in the level of PEPCK mRNA that closely mimicked the effect of treatment
197 omato plants with strongly reduced levels of PEPCK and plastidic NADP-ME were generated by RNA interf
198 ption of hepatic cataplerosis due to loss of PEPCK leads to the accumulation of TCA cycle intermediat
199 iously proposed a model for the mechanism of PEPCK catalysis in which the conformation of this mobile
200 expression, suggesting that the mechanism of PEPCK regulation is, at least in part, dependent on the
201 nt of triglyceride in the skeletal muscle of PEPCK-C(mus) mice were greatly increased as compared wit
202 g AMPK down-regulation and overexpression of PEPCK and G6Pc.
203           We conclude that overexpression of PEPCK-C repatterns energy metabolism and leads to greate
204  expression that involve changes in rates of PEPCK mRNA transcription and degradation.
205   Mice lacking TR4 also display reduction of PEPCK expression with impaired gluconeogenesis.
206 i-1/2, and this blocks insulin regulation of PEPCK and G6Pase expression.
207 or PKB activity in the insulin regulation of PEPCK, G6Pase, and a third insulin-regulated gene, IGF-b
208 ral pathways contribute to the regulation of PEPCK, including the nuclear receptor Rev-erbalpha and t
209 andidate to participate in the regulation of PEPCK.
210 protein that acts as a negative regulator of PEPCK in P. pastoris cultured in biotin-deficient, gluco
211 s that reverse insulin-induced repression of PEPCK transcription.
212 is, rescues the DUSP4-mediated repression of PEPCK.
213 ion of STAT3, a transcriptional repressor of PEPCK.
214 ntrasts a previously determined structure of PEPCK in complex with a triphosphate nucleotide analogue
215  but had no effect on insulin suppression of PEPCK.
216 ulin signaling to decreased transcription of PEPCK and glucose-6-phosphatase (G6Pase) and provides a
217 er is necessary for hepatic transcription of PEPCK-C.
218 ity or levels prevents the effect of DBC1 on PEPCK.
219 gene that antagonized insulin suppression on PEPCK gene transcription from this screen.
220      Upon formation of the PEPCK-Mn2+-PEP or PEPCK-Mn2+-malonate-Mn2+ GDP complexes, C307 coordinatio
221 uconeogenic enzymes glucose-6-phosphatase or PEPCK.
222 nt glucagon-stimulated glucose production or PEPCK expression in hepatocytes lacking STAT3.
223                   Experimental data on other PEPCKs indicate that Arg(81) binds PEP, and the phosphat
224  gluconeogenic enzyme with a cytosolic (Pck1/PEPCK-C) and mitochondrial (Pck2/PEPCK-M) isoform.
225                         To conclude, as Pck2/PEPCK-M is the predominant isoform in C2C12 cells, we po
226 e, phosphoenolpyruvate carboxykinase-M (Pck2/PEPCK-M), increased during treatment with BA, and to a l
227 solic (Pck1/PEPCK-C) and mitochondrial (Pck2/PEPCK-M) isoform.
228 atocytes reduced the T(3) induction of PDK4, PEPCK, and CPT-1a genes.
229                    Although cytosolic PEPCK (PEPCK-C) is absent, PEPCK-M message and protein were det
230 ttributed to the cytosolic isoform of PEPCK (PEPCK-C), although loss of the mitochondrial isoform (PE
231 mall interfering RNA and the pharmacological PEPCK inhibitor 3-mercaptopicolinate significantly enhan
232 ogenesis, indicating Pck2 is the predominant PEPCK isoform.
233 anslational change in a TCDD target protein (PEPCK), and 3) reveals that the AHR exerts complex, prev
234 d increase in endogenous LPA levels, reduced PEPCK levels during fasting, and decreased hepatic gluco
235 G2 cells, whereas a deletion in NS5A reduced PEPCK expression and lowered cellular lipids but was wit
236 7-130 days, hepatic and renal G6P, and renal PEPCK, activities were similar in intact and TX fetuses;
237 lin-induced PKB is required to fully repress PEPCK and G6Pase expression.
238 erestingly, however, hGRbeta did not repress PEPCK in GR liver knockout (GRLKO) mice.
239 to glucagon receptor activation and requires PEPCK-C, thus providing new insights into liver metaboli
240 amuscular route for generating skin-resident PEPCK-specific T cells.
241                                    Silencing PEPCK-M lowers plasma glucose, insulin, and triglyceride
242                               Liver-specific PEPCK knockout mice, which are viable despite markedly a
243 ptor- null mice and mice with liver-specific PEPCK-C deletion.
244 5A in Huh7 or primary hepatocytes stimulated PEPCK gene expression and glucose output in HepG2 cells,
245 cate that C/EBPalpha mediates p38-stimulated PEPCK transcription in liver cells.
246 ucose production (i.e., it fails to suppress PEPCK and other genes of gluconeogenesis), yet it retain
247 ss promoters of enzymes of glucose synthesis PEPCK and G6Pase.
248 t here that TCDD-induced TiPARP also targets PEPCK for ADP-ribosylation.
249 uring dark-induced stomatal closure and that PEPCK is involved in this process.
250 n PEPCK protein, supporting the concept that PEPCK has poor control strength over the gluconeogenic p
251 ses and (13)C carbon tracing to confirm that PEPCK is essential for growth of Mtb on fatty acids and
252 uvate carboxykinase (PEPCK) demonstrate that PEPCK contains a 10-residue Omega-loop domain that acts
253                         We further show that PEPCK is required for growth of Mtb in isolated bone mar
254                                          The PEPCK-C(mus) mice ate 60% more than controls but had hal
255 4alpha stimulation of transcription from the PEPCK-C gene promoter.
256 rol failed to repress transcription from the PEPCK-C gene promoter; overexpression of HNF4alpha in Ch
257 timulated transcription (8-27-fold) from the PEPCK-C gene promoter; this was lost when both SREs were
258 s provides a further illustration of how the PEPCK gene promoter integrates different hormone respons
259 entrations are dramatically increased in the PEPCK null livers.
260 tivation of the cAMP response element in the PEPCK promoter.
261 he glucocorticoid response unit (GRU) in the PEPCK-C gene promoter (-2000 to +73) restrained C/EBP al
262  two SREBP regulatory elements (SREs) in the PEPCK-C gene promoter (-322 to -313 and -590 to -581).
263 ty lipoprotein (LDL) receptor gene (T in the PEPCK-C gene promoter at -582, compared with an A in the
264 ory regions corresponding to the SREs in the PEPCK-C gene promoter.
265 n inhibition as observed with the SRE in the PEPCK-C gene promoter.
266 the binding to nuclear receptor sites in the PEPCK-C gene promoter.
267 ruvate carboxykinase (PEPCK) reported in the PEPCK-Mn2+, -Mn2+-oxaloacetic acid (OAA), -Mn2+-OAA-Mn2+
268                                       In the PEPCK-Mn2+-GTP structure, the same water molecule displa
269 ird conformation of the mobile P-loop in the PEPCK-Mn2+-malonate-Mn2+ GDP complex demonstrates the pa
270 rdering of the mobile active site lid in the PEPCK-Mn2+-malonate-Mn2+ GDP complex yields the first ob
271                                       In the PEPCK-Mn2+-OAA complex, an alternate bound conformation
272 ntroduction of the LDL receptor SRE into the PEPCK-C gene promoter increased SREBP-1c binding and cau
273 ion, in contrast to their stimulation of the PEPCK gene.
274 RNA, which contains the entire 3'-UTR of the PEPCK mRNA, was degraded with a half-life of 1.2 h.
275 hat participate in the rapid turnover of the PEPCK mRNA.
276 hat may contribute to the rapid decay of the PEPCK mRNA.
277 ice using a reporter system comprised of the PEPCK promoter placed upstream of the alkaline phosphata
278 ifically, a reporter system comprised of the PEPCK promoter upstream of alkaline phosphatase was used
279 d SDF-1beta both inhibited activation of the PEPCK promoter.
280 CREB prevented FFA-induced activation of the PEPCK promoter.
281  necessary for FFA-induced activation of the PEPCK promoter.
282 quired for transcriptional repression of the PEPCK-C gene promoter caused by these compounds.
283 pha was the strongest trans-activator of the PEPCK-C gene promoter in the NIH3T3 cell line.
284 the stimulatory effect of Sp1 at -590 of the PEPCK-C gene promoter.
285                        Upon formation of the PEPCK-Mn2+-PEP or PEPCK-Mn2+-malonate-Mn2+ GDP complexes
286  pattern of nucleosomal repositioning on the PEPCK promoter in vitro and in vivo, correlating with NF
287 Ai) in hepatocytes significantly reduced the PEPCK gene expression and glucose production in response
288                                Silencing the PEPCK-M gene completely inhibited GSIS underscoring its
289 uitment of p300 and RNA polymerase II to the PEPCK promoter is increased by the combined Dex/RA treat
290  which decreased its binding affinity to the PEPCK-C gene promoter.
291             During light-dark transients the PEPCK mutant plants show both increased overall stomatal
292                                    Using the PEPCK promoter, we validated the integrity of these temp
293 enzyme activity as 3-MPA interfered with the PEPCK enzyme assay, particularly at 0.5 and 1 mM.
294 opsis PCK1 gene promoter indicated that this PEPCK isoform is specifically expressed in guard cells a
295 boxylase, and that cataplerotic flux through PEPCK is the primary source of [(13)C]bicarbonate.
296                                        Thus, PEPCK-M has a direct role in fasted and fed glucose home
297                        On a mouse treadmill, PEPCK-C(mus) mice ran up to 6 km at a speed of 20 m/min,
298                                Unexpectedly, PEPCK also increased the synthesis of ribose from non-ca
299               The interaction of Mg-IDP with PEPCK is dependent upon a single acidic ionization attri
300  the interaction of phosphoenolpyruvate with PEPCK and a single basic ionization with a pK(a) value o

 
Page Top